Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster.
Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster. The Danish drugmaker has ...
Zacks.com on MSN5mon
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which ...
Pharmaceutical company Lundbeck will acquire Nasdaq-listed Longboard Pharmaceuticals in a $2.6 billion deal, the two companies said Monday. Denmark-listed H. Lundbeck will make a tender offer for ...
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback